Literature DB >> 7340990

Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin.

J H Peters, G R Gordon, D Kashiwase, E M Acton.   

Abstract

Plasma and tissue levels of doxorubicin (DXR) and doxorubicinol (DXR-OL) were measured fluorometrically after high-pressure liquid chromatography at 1, 3, and 24 h following one, nine, and 24 doses of 1.0 mg DXR/kg or one and eight doses of 4.0 mg DXR/kg, IP, to rats. Comparison of plasma levels of DXR found following single and multiple doses suggests significant build-up of DXR at 1 h with successive doses, but not at 3 h. Liver exhibited substantially higher levels of DXR (on a per gram of protein basis) than did plasma, and multiple doses did not produce higher levels than did a single dose. In contrast, the heart accumulated DXR slowly, attaining levels after multiple dosing in excess of those found in the liver. Skeletal muscle exhibited dose-related levels similar to those for heart but the absolute levels of DXR in muscle were only about one-tenth of those observed in heart. DXR-OL was at very low levels of less than or equal to 4% of the DXR levels in the tissues; it was, however, a major circulatory metabolite, attaining levels in the plasma as high as 85% of the concentration of DXR.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7340990     DOI: 10.1007/bf00258216

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Quantitation of submicrogram quantities of protein by an improved protein-dye binding assay.

Authors:  J C Bearden
Journal:  Biochim Biophys Acta       Date:  1978-04-26

3.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

4.  Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.

Authors:  A J Weiss; G E Metter; W S Fletcher; W L Wilson; T B Grage; G Ramirez
Journal:  Cancer Treat Rep       Date:  1976-07

Review 5.  Model systems for cardiotoxic effects of anthracyclines.

Authors:  G Zbinden; E Bachmann; C Holderegger
Journal:  Antibiot Chemother (1971)       Date:  1978

6.  Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity.

Authors:  A J Weiss; R W Manthel
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

7.  Synthesis of daunorubicin analogues with novel 9-acyl substituents.

Authors:  T H Smith; A N Fujiwara; D W Henry
Journal:  J Med Chem       Date:  1979-01       Impact factor: 7.446

8.  Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography.

Authors:  S Shinozawa; Y Mimaki; Y Araki; T Oda
Journal:  J Chromatogr       Date:  1980-08-29

9.  Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model.

Authors:  K K Chan; J L Cohen; J F Gross; K J Himmelstein; J R Bateman; Y Tsu-Lee; A S Marlis
Journal:  Cancer Treat Rep       Date:  1978-08

10.  Chronic cardiotoxicity of doxorubicin (adriamycin) in the rat: morphologic and biochemical investigations.

Authors:  H M Olson; C C Capen
Journal:  Toxicol Appl Pharmacol       Date:  1978-06       Impact factor: 4.219

View more
  15 in total

1.  Physiological pharmacokinetic model of adriamycin delivered via magnetic albumin microspheres in the rat.

Authors:  J M Gallo; C T Hung; P K Gupta; D G Perrier
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

2.  Delivery of therapeutic doses of doxorubicin to the mouse lung using lung-accumulating liposomes proves unsuccessful.

Authors:  R M Abra; C A Hunt; K K Fu; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity.

Authors:  Maria A Mitry; Dimitri Laurent; Britny L Keith; Elizabeth Sira; Carol A Eisenberg; Leonard M Eisenberg; Sachindra Joshi; Sachin Gupte; John G Edwards
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

4.  Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol.

Authors:  R Danesi; A Marchetti; N Bernardini; R V La Rocca; G Bevilacqua; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.

Authors:  G Minotti; A F Cavaliere; A Mordente; M Rossi; R Schiavello; R Zamparelli; G Possati
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 6.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

7.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.

Authors:  B J Cusack; D A Tesnohlidek; V L Loseke; R E Vestal; D E Brenner; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.

Authors:  R D Olson; P S Mushlin; D E Brenner; S Fleischer; B J Cusack; B K Chang; R J Boucek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

10.  Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.

Authors:  P Gunvén; N O Theve; C Peterson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.